Identification of AKAP-4 as a new cancer/testis antigen for detection and immunotherapy of prostate cancer

Prostate

Volumn 72, Issue 1, 2012, Pages 12-23

  Chiriva Internati, Maurizio ^a,b   Yu, Yuefei ^a   Mirandola, Leonardo ^a   D'Cunha, Nicholas ^a   Hardwicke, Fred ^a   Cannon, Martin J ^c   Cobos, Everardo ^a   Kast, W Martin ^b,d,e  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b Kiromic Inc   (United States)

^c UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e UNIVERSITY OF HAWAII CANCER CENTER   (United States)

Author keywords

AKAP; biomarkers; cancer testis antigens; immune surveillance; immunotherapy; prostate cancer

Indexed keywords

AKAP 4 PROTEIN; GAMMA INTERFERON; IMMUNOGLOBULIN; INTERLEUKIN 10; INTERLEUKIN 4; INTERLEUKIN 5; MESSENGER RNA; TUMOR MARKER; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ARTICLE; BLOOD SAMPLING; CANCER DIAGNOSIS; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOGENICITY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROSTATE; PROSTATE CANCER; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

A KINASE ANCHOR PROTEINS; CELL LINE, TUMOR; HUMANS; IMMUNOTHERAPY; MALE; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TESTIS;

EID: 81855194457     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21400     Document Type: Article

References (61)

1. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P,. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007; 18 (3): 581-592.
2. Leman ES, Getzenberg RH,. Biomarkers for prostate cancer. J Cell Biochem 2009; 108 (1): 3-9.
3. Ferro MA, Barnes I, Roberts JB, Smith PJ,. Tumour markers in prostatic carcinoma. A comparison of prostate-specific antigen with acid phosphatase. Br J Urol 1987; 60 (1): 69-73.
4. Constantinou J, Feneley MR,. PSA testing: An evolving relationship with prostate cancer screening. Prostate Cancer Prostatic Dis 2006; 9 (1): 6-13.
5. Barry MJ,. Clinical practice. Prostate-specific-antigen testing for early diagnosis of prostate cancer. N Engl J Med 2001; 344 (18): 1373-1377.
6. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, Minasian LM, Ford LG, Lippman SM, Crawford ED, Crowley JJ, Coltman CA Jr., Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med 2004; 350 (22): 2239-2246.
7. Drake CG,. Prostate cancer as a model for tumour immunotherapy. Nat Rev Immunol 2010; 10 (8): 580-593.
8. Riedmann EM,. World's first cancer vaccine licensed: PROVENGE((R)). Hum Vaccine 2010; 6: 6.
9. Chiriva-Internati M, Grizzi F, Wachtel MS, Jenkins M, Ferrari R, Cobos E, Frezza EE,. Biological treatment for liver tumor and new potential biomarkers. Dig Dis Sci 2008; 53 (3): 836-843.
10. Chiriva-Internati M, Grizzi F, Weidanz JA, Ferrari R, Yuefei Y, Velez B, Shearer MH, Lowe DB, Frezza EE, Cobos E, Kast WM, Kennedy RC,. A NOD/SCID tumor model for human ovarian cancer that allows tracking of tumor progression through the biomarker Sp17. J Immunol Methods 2007; 321 (1-2): 86-93.
11. Straughn JM Jr, Shaw DR, Guerrero A, Bhoola SM, Racelis A, Wang Z, Chiriva-Internati M, Grizzle WE, Alvarez RD, Lim SH, Strong TV,. Expression of sperm protein 17 (Sp17) in ovarian cancer. Int J Cancer 2004; 108 (6): 805-811.
12. Dannull J, Diener PA, Prikler L, Furstenberger G, Cerny T, Schmid U, Ackermann DK, Groettrup M,. Prostate stem cell antigen is a promising candidate for immunotherapy of advanced prostate cancer. Cancer Res 2000; 60 (19): 5522-5528.
13. Harada M, Kobayashi K, Matsueda S, Nakagawa M, Noguchi M, Itoh K,. Prostate-specific antigen-derived epitopes capable of inducing cellular and humoral responses in HLA-A24+ prostate cancer patients. Prostate 2003; 57 (2): 152-159.
14. Lu J, Celis E,. Recognition of prostate tumor cells by cytotoxic T lymphocytes specific for prostate-specific membrane antigen. Cancer Res 2002; 62 (20): 5807-5812.
15. Peshwa MV, Shi JD, Ruegg C, Laus R, van Schooten WC,. Induction of prostate tumor-specific CD8+ cytotoxic T-lymphocytes in vitro using antigen-presenting cells pulsed with prostatic acid phosphatase peptide. Prostate 1998; 36 (2): 129-138.
16. Chiriva-Internati M, Ferrari R, Prabhakar M, Yu Y, Baggoni L, Moreno J, Gagliano N, Portinaro N, Jenkins MR, Frezza EE, Hardwicke F, D'Cunha N, Kast W, Cobos E,. The pituitary tumor transforming gene 1 (PTTG-1): An immunological target for multiple myeloma. J Transl Med 2008; 6: 15.
17. Chiriva-Internati M, Weidanz JA, Yu Y, Frezza EE, Jenkins MR, Kennedy RC, Cobos E, Kast WM,. Sperm protein 17 is a suitable target for adoptive T-cell-based immunotherapy in human ovarian cancer. J Immunother 2008; 31 (8): 693-703.
18. Gray A, Raff AB, Chiriva-Internati M, Chen SY, Kast WM,. A paradigm shift in therapeutic vaccination of cancer patients: The need to apply therapeutic vaccination strategies in the preventive setting. Immunol Rev 2008; 222: 316-327.
19. Yu Y, Pilgrim P, Zhou W, Gagliano N, Frezza EE, Jenkins M, Weidanz JA, Lustgarten J, Cannon M, Bumm K, Cobos E, Kast WM, Chiriva-Internati M,. rAAV/Her-2/neu loading of dendritic cells for a potent cellular-mediated MHC class I restricted immune response against ovarian cancer. Viral Immunol 2008; 21 (4): 435-442.
20. Chiriva-Internati M, Wang Z, Pochopien S, Salati E, Lim SH,. Identification of a sperm protein 17 CTL epitope restricted by HLA-A1. Int J Cancer 2003; 107 (5): 863-865.
21. Chiriva-Internati M, Wang Z, Salati E, Wroblewski D, Lim SH,. Successful generation of sperm protein 17 (Sp17)-specific cytotoxic T lymphocytes from normal donors: Implication for tumour-specific adoptive immunotherapy following allogeneic stem cell transplantation for Sp17-positive multiple myeloma. Scand J Immunol 2002; 56 (4): 429-433.
22. Chiriva-Internati M, Wang Z, Xue Y, Bumm K, Hahn AB, Lim SH,. Sperm protein 17 (Sp17) in multiple myeloma: Opportunity for myeloma-specific donor T cell infusion to enhance graft-versus-myeloma effect without increasing graft-versus-host disease risk. Eur J Immunol 2001; 31 (8): 2277-2283.
23. Lim SH, Wang Z, Chiriva-Internati M, Xue Y,. Sperm protein 17 is a novel cancer-testis antigen in multiple myeloma. Blood 2001; 97 (5): 1508-1510.
24. Fossa A, Alsoe L, Crameri R, Funderud S, Gaudernack G, Smeland EB,. Serological cloning of cancer/testis antigens expressed in prostate cancer using cDNA phage surface display. Cancer Immunol Immunother 2004; 53 (5): 431-438.
25. Fossa A, Berner A, Fossa SD, Hernes E, Gaudernack G, Smeland EB,. NY-ESO-1 protein expression and humoral immune responses in prostate cancer. Prostate 2004; 59 (4): 440-447.
26. Parmigiani RB, Bettoni F, Vibranovski MD, Lopes MH, Martins WK, Cunha IW, Soares FA, Simpson AJ, de Souza SJ, Camargo AA,. Characterization of a cancer/testis (CT) antigen gene family capable of eliciting humoral response in cancer patients. Proc Natl Acad Sci USA 2006; 103 (48): 18066-18071.
27. Sampson N, Untergasser G, Lilg C, Tadic L, Plas E, Berger P,. GAGEC1, a cancer/testis associated antigen family member, is a target of TGF-beta1 in age-related prostatic disease. Mech Ageing Dev 2007; 128 (1): 64-66.
28. Scanlan MJ, Simpson AJ, Old LJ,. The cancer/testis genes: Review, standardization, and commentary. Cancer Immun 2004; 4: 1.
29. Jin J, Smith FD, Stark C, Wells CD, Fawcett JP, Kulkarni S, Metalnikov P, O'Donnell P, Taylor P, Taylor L, Zougman A, Woodgett JR, Langeberg LK, Scott JD, Pawson T,. Proteomic, functional, and domain-based analysis of in vivo 14-3-3 binding proteins involved in cytoskeletal regulation and cellular organization. Curr Biol 2004; 14 (16): 1436-1450.
30. Turner RM, Musse MP, Mandal A, Klotz K, Jayes FC, Herr JC, Gerton GL, Moss SB, Chemes HE,. Molecular genetic analysis of two human sperm fibrous sheath proteins, AKAP4 and AKAP3, in men with dysplasia of the fibrous sheath. J Androl 2001; 22 (2): 302-315.
31. Chiriva-Internati M, Ferrari R, Yu Y, Hamrick C, Gagliano N, Grizzi F, Frezza E, Jenkins MR, Hardwick F, D'Cunha N, Kast WM, Cobos E,. AKAP-4: A novel cancer testis antigen for multiple myeloma. Br J Haematol 2008; 140 (4): 465-468.
32. Sabbisetti VS, Chirugupati S, Thomas S, Vaidya KS, Reardon D, Chiriva-Internati M, Iczkowski KA, Shah GV,. Calcitonin increases invasiveness of prostate cancer cells: Role for cyclic AMP-dependent protein kinase A in calcitonin action. Int J Cancer 2005; 117 (4): 551-560.
33. Pitkanen-Arsiola T, Tillman JE, Gu G, Yuan J, Roberts RL, Wantroba M, Coetzee GA, Cookson MS, Kasper S,. Androgen and anti-androgen treatment modulates androgen receptor activity and DJ-1 stability. Prostate 2006; 66 (11): 1177-1193.
34. Hayward S, Cox S, Mitchell I, Hallowes R, Deshpande N, Towler J,. The effects of interferons on the activity of alpha-glycerolphosphate dehydrogenase in benign prostatic hyperplasia cells in primary culture. J Urol 1987; 138 (3): 648-653.
35. Yang JS, Kim HJ, Ryu YH, Yun CH, Chung DK, Han SH,. Endotoxin contamination in commercially available pokeweed mitogen contributes to the activation of murine macrophages and human dendritic cell maturation. Clin Vaccine Immunol 2006; 13 (3): 309-313.
36. Grizzi F, Gaetani P, Franceschini B, Di Ieva A, Colombo P, Ceva-Grimaldi G, Bollati A, Frezza EE, Cobos E, Rodriguez y, Baena R, Dioguardi N, Chiriva-Internati M,. Sperm protein 17 is expressed in human nervous system tumours. BMC Cancer 2006; 6: 23.
37. Chiriva-Internati M, Wang Z, Salati E, Bumm K, Barlogie B, Lim SH,. Sperm protein 17 (Sp17) is a suitable target for immunotherapy of multiple myeloma. Blood 2002; 100 (3): 961-965.
38. Santin AD, Hermonat PL, Ravaggi A, Chiriva-Internati M, Zhan D, Pecorelli S, Parham GP, Cannon MJ,. Induction of human papillomavirus-specific CD4(+) and CD8(+) lymphocytes by E7-pulsed autologous dendritic cells in patients with human papillomavirus type 16-and 18-positive cervical cancer. J Virol 1999; 73 (7): 5402-5410.
39. Chiriva-Internati M, Cobos E, Kast WM,. Advances in immunotherapy of multiple myeloma: From the discovery of tumor-associated antigens to clinical trials. Int Rev Immunol 2007; 26 (3-4): 197-222.
40. Lewis TE, Milam TD, Klingler DW, Rao PS, Jaggi M, Smith DJ, Hemstreet GP, Balaji KC,. Tissue transglutaminase interacts with protein kinase A anchor protein 13 in prostate cancer. Urol Oncol 2005; 23 (6): 407-412.
41. Kim SH, Lee S, Lee CH, Lee MK, Kim YD, Shin DH, Choi KU, Kim JY, Park do Y, Sol MY,. Expression of cancer-testis antigens MAGE-A3/6 and NY-ESO-1 in non-small-cell lung carcinomas and their relationship with immune cell infiltration. Lung 2009; 187 (6): 401-411.
42. Miles AK, Rogers A, Li G, Seth R, Powe D, McArdle SE, McCulloch TA, Bishop MC, Rees RC,. Identification of a novel prostate cancer-associated tumor antigen. Prostate 2007; 67 (3): 274-287.
43. McNeel DG, Nguyen LD, Storer BE, Vessella R, Lange PH, Disis ML,. Antibody immunity to prostate cancer associated antigens can be detected in the serum of patients with prostate cancer. J Urol 2000; 164 (5): 1825-1829.
44. Korangy F, Ormandy LA, Bleck JS, Klempnauer J, Wilkens L, Manns MP, Greten TF,. Spontaneous tumor-specific humoral and cellular immune responses to NY-ESO-1 in hepatocellular carcinoma. Clin Cancer Res 2004; 10 (13): 4332-4341.
45. Jager D, Jager E, Knuth A,. Immune responses to tumour antigens: Implications for antigen specific immunotherapy of cancer. J Clin Pathol 2001; 54 (9): 669-674.
46. Liu WM, Fowler DW, Smith P, Dalgleish AG,. Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses. Br J Cancer 2010; 102 (1): 115-123.
47. Dranoff G,. Targets of protective tumor immunity. Ann N Y Acad Sci 2009; 1174: 74-80.
48. Hildner K, Edelson BT, Purtha WE, Diamond M, Matsushita H, Kohyama M, Calderon B, Schraml BU, Unanue ER, Diamond MS, Schreiber RD, Murphy TL, Murphy KM,. Batf3 deficiency reveals a critical role for CD8alpha+ dendritic cells in cytotoxic T cell immunity. Science 2008; 322 (5904): 1097-1100.
49. Zhou H, Luo Y, Mizutani M, Mizutani N, Reisfeld RA, Xiang R,. T cell-mediated suppression of angiogenesis results in tumor protective immunity. Blood 2005; 106 (6): 2026-2032.
50. Cha E, Fong L,. Therapeutic vaccines for prostate cancer. Curr Opin Mol Ther 2010; 12 (1): 77-85.
51. Chiriva-Internati M, Liu Y, Weidanz JA, Grizzi F, You H, Zhou W, Bumm K, Barlogie B, Mehta JL, Hermonat PL,. Testing recombinant adeno-associated virus-gene loading of dendritic cells for generating potent cytotoxic T lymphocytes against a prototype self-antigen, multiple myeloma HM1.24. Blood 2003; 102 (9): 3100-3107.
52. Chiriva-Internati M, Wang Z, Salati E, Timmins P, Lim SH,. Tumor vaccine for ovarian carcinoma targeting sperm protein 17. Cancer 2002; 94 (9): 2447-2453.
53. Zhu J, Paul WE,. Heterogeneity and plasticity of T helper cells. Cell Res 20 (1): 4-12.
54. Murakami H, Ogawara H, Hiroshi H,. Th1/Th2 cells in patients with multiple myeloma. Hematology 2004; 9 (1): 41-45.
55. Garcia-Hernandez Mde L, Gray A, Hubby B, Klinger OJ, Kast WM,. Prostate stem cell antigen vaccination induces a long-term protective immune response against prostate cancer in the absence of autoimmunity. Cancer Res 2008; 68 (3): 861-869.
56. Pantuck AJ, van Ophoven A, Gitlitz BJ, Tso CL, Acres B, Squiban P, Ross ME, Belldegrun AS, Figlin RA,. Phase I trial of antigen-specific gene therapy using a recombinant vaccinia virus encoding MUC-1 and IL-2 in MUC-1-positive patients with advanced prostate cancer. J Immunother 2004; 27 (3): 240-253.
57. Allam M, Julien N, Zacharie B, Penney C, Gagnon L,. Enhancement of Th1 type cytokine production and primary T cell activation by PBI-1393. Clin Immunol 2007; 125 (3): 318-327.
58. Lee SO, Pinder E, Chun JY, Lou W, Sun M, Gao AC,. Interleukin-4 stimulates androgen-independent growth in LNCaP human prostate cancer cells. Prostate 2008; 68 (1): 85-91.
59. Ebelt K, Babaryka G, Figel AM, Pohla H, Buchner A, Stief CG, Eisenmenger W, Kirchner T, Schendel DJ, Noessner E,. Dominance of CD4+ lymphocytic infiltrates with disturbed effector cell characteristics in the tumor microenvironment of prostate carcinoma. Prostate 2008; 68 (1): 1-10.
60. Ebelt K, Babaryka G, Frankenberger B, Stief CG, Eisenmenger W, Kirchner T, Schendel DJ, Noessner E,. Prostate cancer lesions are surrounded by FOXP3+, PD-1+ and B7-H1+ lymphocyte clusters. Eur J Cancer 2009; 45 (9): 1664-1672.
61. Miller AM, Lundberg K, Ozenci V, Banham AH, Hellstrom M, Egevad L, Pisa P,. CD4+CD25high T cells are enriched in the tumor and peripheral blood of prostate cancer patients. J Immunol 2006; 177 (10): 7398-7405.